Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
Jul 3, 2024Toripalimab becomes Apotex's first novel brand biologic medicine
TORONTO, July 2, 2024 /CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced an exclusive agreement with Coherus Biosciences, Inc. ("Coherus") to license Canadian rights to toripalimab, an anti-PD-1 monoclonal antibody, under which Apotex will market and distribute toripalimab, in Canada upon approval. The agreement further expands Apotex's oncology franchise, with toripalimab becoming Apotex's first novel brand biologic medicine in its portfolio.
"Through this licensing agreement with Coherus on toripalimab, and upon approval of the new drug submission, we will provide a new treatment option to patients with nasopharyngeal carcinoma in Canada," said Allan Oberman, President & CEO, Apotex. "Our introduction of toripalimab to the Canadian market is aligned with our strategic focus of further expanding our innovative branded pharmaceutical therapeutic areas as we advance our vision of becoming a Canadian-based global health company."
Under the terms of the agreement, Apotex has exclusive rights to commercialize toripalimab within Canada. Apotex will be responsible for obtaining marketing authorization for toripalimab in Canada and plans to seek approval for toripalimab as a treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Coherus will receive certain payments under the agreement, including an upfront payment and milestone payments upon achievement of certain regulatory and sales milestones.
About toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates anti-tumor immunity. Toripalimab, approved in the U.S. as LOQTORZI® (toripalimab-tpzi), is indicated in combination with cisplatin and gemcitabine for first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) and as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy. For more information about LOQTORZI, including the U.S. Prescribing Information, and indications and important safety information, please visit www.loqtorzi.com.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for consumers worldwide, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceutical products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
Media inquiries: Contact Apotex Media, [email protected]
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.